The emerging role of melatonin agonists in the treatment of major depression: Focus on agomelatine

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 1, 2011, Pages 119-132

  de Berardis, Domenico ^a,b   Di Iorio, Giuseppe ^a   Acciavatti, Tiziano ^a   Conti, Chiara ^a   Serroni, Nicola ^b   Olivieri, Luigi ^b   Cavuto, Marilde ^c   Martinotti, Giovanni ^d   Janiri, Luigi ^d   Moschetta, Francesco Saverio ^b   Conti, Pio ^a   Di Giannantonio, Massimo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b G Mazzini Hospital   (Italy)

^c Istituto Abruzzese di Storia Musicale (IASM)   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Agomelatine; Circadian rhythms; Efficacy; Major depressive disorder; Melatonin; Tolerability; Treatment

Indexed keywords

AGOMELATINE; FLUOXETINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT;

AFFECTIVE PSYCHOSIS; ANXIETY DISORDER; BACKACHE; CIRCADIAN RHYTHM; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR DEPRESSION; MIGRAINE; NAUSEA; REVIEW; SOMNOLENCE; UPPER ABDOMINAL PAIN; CLINICAL TRIAL (TOPIC); DRUG POTENTIATION; METABOLISM; PATHOPHYSIOLOGY;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; MELATONIN; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2;

EID: 79954633976     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711794488674     Document Type: Review

References (153)

1. Belmaker, R.H.; Agam, G. Major depressive disorder. N. Engl. J. Med., 2008, 358, 55-68
2. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry, 2005, 62, 593-602
3. Kessler, R.C.; Chiu, W.T.; Demler, O.; Merikangas, K.R.; Walters, E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry, 2005, 62, 617-627
4. Gorwood P. Severe depression: genes and the environment. Encephale, 2009, 35(Suppl 7), 306-309
5. Krishnan, V.; Nestler, E.J. The molecular neurobiology of depression. Nature, 2008, 16, 894-902
6. Papakostas, G.I. The efficacy, tolerability, and safety of contemporary antidepressants. J. Clin. Psychiatry, 2010, 71(Suppl E1), e03
7. Warden, D.; Rush, A.J.; Trivedi, M.H.; Fava, M.; Wisniewski, S.R. The STAR*D Project results: a comprehensive review of findings. Curr. Psychiatry Rep., 2007, 9, 449-459
8. Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A.; Stewart, J.W.; Warden, D.; Niederehe, G.; Thase, M.E.; Lavori, P.W.; Lebowitz, B.D.; McGrath, P.J.; Rosenbaum, J.F.; Sackeim, H.A.; Kupfer, D.J.; Luther, J.; Fava, M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry, 2006, 163, 1905-1917
9. Serretti, A.; Chiesa, A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J. Clin. Psychopharmacol., 2009, 29, 259-266
10. Soria, V.; Urretavizcaya, M. Circadian rhythms and depression. Actas Esp. Psiquiatr., 2009, 37, 222-232
11. Kálmán, J.; Kálmán, S. Depression as chronobiological illness. Neuropsychopharmacol. Hung., 2009, 11, 69-81
12. Dubovsky, S.L.; Warren, C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin. Investig. Drugs, 2009, 18, 1533-1540
13. Schulz, P.; Steimer, T. Neurobiology of circadian systems. CNS Drugs, 2009, 23(Suppl 2), 3-13
14. Cermakian, N.; Boivin, D.B. The regulation of central and peripheral circadian clocks in humans. Obes. Rev., 2009, 10(Suppl 2), 25-36
15. Saper, C.B.; Lu, J.; Chou, T.C.; Gooley, J. The hypothalamic integrator for circadian rhythms. Trends Neurosci., 2005, 28, 152-157
16. Benarroch, E.E. Suprachiasmatic nucleus and melatonin: reciprocal interactions and clinical correlations. Neurology, 2008, 71, 594-598
17. Moore, R.Y. Circadian rhythms: basic neurobiology and clinical applications. Annu. Rev. Med., 1997, 48, 253-266
18. Troein, C.; Locke, J.C.; Turner, M.S.; Millar, A.J. Weather and seasons together demand complex biological clocks. Curr. Biol., 2009, 19, 1961-1964
19. Zee, P.C.; Manthena, P. The brain's master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med. Rev., 2007, 11, 59-70
20. Khalsa, S.B.; Jewett, M.E.; Cajochen, C.; Czeisler, C.A. A phase response curve to single bright light pulses in human subjects. J. Physiol., 2003, 549, 945-952
21. Duguay, D.; Cermakian, N. The crosstalk between physiology and circadian clock proteins. Chronobiol. Int., 2009, 26, 1479-1513
22. Schibler, U.; Ripperger, J.; Brown, S.A. Peripheral circadian oscillators in mammals: time and food. J. Biol. Rhythms, 2003, 18, 250-260
23. Brainard, G.C.; Hanifin, J.P.; Greeson, J.M.; Byrne, B.; Glickman, G.; Gerner, E.; Rollag, M.D. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J. Neurosci., 2002, 21, 6405-6412
24. Pandi-Perumal, S.R.; Srinivasan, V.; Maestroni, G.J.M.; Cardinali, D.P.; Poeggeler, B.; Hardeland, R. Melatonin: nature's most versatile biological signal? FEBS J., 2006, 273, 2813-2838
25. Macchi, M.M.; Bruce, J.N. Human pineal physiology and functional significance of melatonin. Front. Neuroendocrinol., 2004, 25, 177-195
26. Mody, S.M.; Hu, Y.; Ho, M.K.; Wong, Y.H. In search of novel and therapeutically significant melatoninergic ligands. Recent Pat. CNS Drug. Discov., 2007, 2, 241-245
27. Reppert, S.M.; Weaver, D.R.; Godson, C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci., 1996, 17, 100-102
28. Dubocovich, M.L.; Rivera-Bermudez, M.A.; Gerdin, M.J.; Masana, M.I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci., 2003, 8, 101-108
29. Witt-Enderby, P.A.; Bennett, J.; Jarzynka, M.J.; Firestine, S.; Melan, M.A. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci., 2003, 72, 2183-2198
30. Liu, C.; Weaver, D.R.; Jin, X.; Shearman, L.P.; Pieschl, R.L.; Gribkoff, V.K.; Reppert, S.M. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron, 1997, 19, 91-102
31. Van den Top, M.; Buijs, R.M.; Ruijter, J.M.; Delagrange, P.; Spanswick, D.; Hermes, M.L. Melatonin generates an outward potassium current in rat suprachiasmatic nucleus neurones in vitro independent of their circadian rhythm. Neuroscience, 2001, 107, 99-108
32. von Gall, C.; Weaver, D.R. Loss of responsiveness to melatonin in the aging mouse suprachiasmatic nucleus. Neurobiol. Aging, 2008, 29, 464-470
33. Golombek, D.A.; Pévet, P.; Cardinali, D.P. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci. Biobehav. Rev., 1996, 20, 403-412
34. Zawilska, J.B.; Skene, D.J.; Arendt, J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol. Rep., 2009, 61, 383-410
35. Dubocovich, M.L.; Yun, K.; Al-Ghoul, W.M.; Benloucif, S.; Masana, M.I. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J., 1998, 12, 1211-1220
36. Hunt, A.E.; Al-Ghoul, W.M.; Gillette, M.U.; Dubocovich, M.L. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol. Cell Physiol., 2001, 280, 110-118
37. Masana, M.I.; Benloucif, S.; Dubocovich, M.L. Circadian rhythm of MT1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J. Pineal Res., 2000, 28, 185-192
38. Poirel, V.J.; Masson-Pévet, M.; Pevét, P.; Gauer, F. MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei. Brain Res., 2002, 946, 64-71
39. Lee, H.S.; Billings, H.J.; Lehman, M.N. The suprachiasmatic nucleus: a clock of multiple components. J. Biol. Rhythms, 2003, 18, 435-449
40. Challet, E. Entrainment of the suprachiasmatic clockwork in diurnal and nocturnal mammals. Endocrinology, 2007, 148, 5648-5655
41. Pandi-Perumal, S.R.; Srinivasan, V.; Spence, D.W.; Cardinali, D.P. Role of melatonin system in the control of sleep. CNS Drugs, 2007, 21, 995-1018
42. Turek, F.W. From circadian rhythms to clock genes in depression. Int. Clin. Psychopharmacol., 2007, 22(Suppl 2), 1-8
43. Morris, D.W.; Trivedi, M.H.; Fava, M.; Wisniewski, S.R.; Balasubramani, G.K.; Khan, A.Y.; Jain, S.; Rush, A.J. Diurnal mood variation in outpatients with major depressive disorder. Depress. Anxiety, 2009, 26, 851-863
44. Grandin, L.D.; Alloy, L.B.; Abramson, L.Y. The social zeitgeber theory, circadian rhythms, and mood disorders: review and evaluation. Clin. Psychol. Rev., 2006, 26, 679-694
45. Murray, G. Diurnal mood variation in depression: a signal of disturbed circadian function? J. Affect. Disord., 2007, 102, 47-53
46. Tsujimoto, T.; Yamada, N.; Shimoda, K.; Kanada, K.; Takahashi, S. Circadian rhythms in depression. Part II: circadian rhythms in inpatients with various mental disorders. J. Affect. Disord., 1990, 18, 199-210
47. Mendlewicz, J. Disruption of the circadian timing systems: molecular mechanisms in mood disorders. CNS Drugs, 2009, 23(Suppl 2), 15-26
48. Van Cauter, E.; Leproult, R.; Kupfer, D.J. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J. Clin. Endocrinol. Metab., 1996, 81, 2468-2473
49. Pacchierotti, C.; Iapichino, S.; Bossini, L.; Pieraccini, F.; Castrogiovanni, P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front. Neuroendocrinol., 2001, 22, 18-32
50. Palazidou, E.; Papadopoulos, A.; Ratcliff, H.; Dawling, S.; Checkley, S.A. NE uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients. Psychol. Med., 1992, 22, 309-315
51. Mitchell, H.A.; Weinshenker, D. Good night and good luck: norepinephrine in sleep pharmacology. Biochem. Pharmacol., 2009, 79(6), 801-809
52. Kripke, D.F.; Youngstedt, S.D.; Rex, K.M.; Klauber, M.R.; Elliott, J.A. Melatonin excretion with affect disorders over age 60. Psychiatry Res., 2003, 118, 47-54
53. Carvalho, L.A.; Gorenstein, C.; Moreno, R.A.; Markus, R.P. Melatonin levels in drug-free patients with major depression from the southern hemisphere. Psychoneuroendocrinology, 2006, 31, 761-768
54. Carvalho, L.A.; Gorenstein, C.; Moreno, R.; Pariante, C.; Markus, R.P. Effect of antidepressants on melatonin metabolite in depressed patients. J. Psychopharmacol., 2009, 23, 315-321
55. Dalton, E.J.; Rotondi, D.; Levitan, R.D.; Kennedy, S.H.; Brown, G.M. Use of slow-release melatonin in treatment-resistant depression. J. Psychiatry Neurosci., 2000, 25, 48-52
56. Wetterberg, L. Clinical importance of melatonin. Prog. Brain Res., 1979, 52, 539-547
57. Claustrat, B.; Chazot, G.; Brun, J.; Jordan, D.; Sassolas, G. A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol. Psychiatry, 1984, 19, 1215-1228
58. Nair, N.P.; Hariharasubramanian, N. Circadian rhythms and psychiatry. Br. J. Psychiatry, 1984, 145, 557-558
59. Brown, R.; Kocsis, J.H.; Caroff, S.; Amsterdam, J.; Winokur, A.; Stokes, P.E.; Frazer, A. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am. J. Psychiatry, 1985, 142, 811-816
60. Beck-Friis, J.; Kjellman, B.F.; Aperia, B.; Undén, F.; von Rosen, D.; Ljunggren, J.G.; Wetterberg, L. Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr. Scand., 1985, 71, 319-330
61. Lewy, A.J.; Sack, R.L. The phase-shift hypothesis of seasonal affective disorder. Am. J. Psychiatry, 1988, 145, 1041-1043
62. Rubin, R.T.; Heist, E.K.; McGeoy, S.S.; Hanada, K.; Lesser, I.M. Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects. Arch. Gen. Psychiatry, 1992, 49, 558-567
63. Shafii, M.; MacMillan, D.R.; Key, M.P.; Derrick, A.M.; Kaufman, N.; Nahinsky, I.D. Nocturnal serum melatonin profile in major depression in children and adolescents. Arch. Gen. Psychiatry, 1996, 53, 1009-1013
64. Sekula, L.K.; Lucke, J.F.; Heist, E.K.; Czambel, R.K.; Rubin, R.T. Neuroendocrine aspects of primary endogenous depression. XV: Mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls. Psychiatry Res., 1997, 69, 143-153
65. Crasson, M.; Kjiri, S.; Colin, A.; Kjiri, K.; L'Hermite-Baleriaux, M.; Ansseau, M.; Legros, J.J. Serum melatonin and urinary 6- sulfatoxymelatonin in major depression. Psychoneuroendocrinology, 2004, 29, 1-12
66. Koorengevel, K.M.; Beersma, D.G.; den Boer, J.A.; van den Hoofdakker, R.H. A forced desynchrony study of circadian pacemaker characteristics in seasonal affective disorder. J. Biol. Rhythms, 2002, 17, 463-475
67. Sher, L. Etiology, pathogenesis, and treatment of seasonal and nonseasonal mood disorders: possible role of circadian rhythm abnormalities related to developmental alcohol exposure. Med. Hypotheses, 2004, 62, 797-801
68. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, Text Revision (DSM-IV-TR); American Psychiatric Press: Washington, DC, 2000
69. Sohn, C.H.; Lam, R.W. Update on the biology of seasonal affective disorder. CNS Spectr., 2005, 10, 635-646
70. Axelsson, J.; Káradóttir, R.; Karlsson, M.M. Differences in prevalence of seasonal affective disorder that are not explained by either genetic or latitude differences. Int. J. Circumpolar Health, 2002, 61, 17-20
71. Magnusson, A.; Boivin, D. Seasonal affective disorder: an overview. Chronobiol. Int., 2003, 20, 189-207
72. Rosenthal, N.E.; Sack, D.A.; Gillin, J.C.; Lewy, A.J.; Goodwin, F.K.; Davenport, Y.; Mueller, P.S.; Newsome, D.A.; Wehr, T.A. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch. Gen. Psychiatry, 1984, 41, 72-80
73. Lewy, A.J.; Bauer, V.K.; Cutler, N.L.; Sack, R.L. Melatonin treatment of winter depression: a pilot study. Psychiatry Res., 1998, 77, 57-61
74. Sack, R.L.; Lewy, A.J.; White, D.M.; Singer, C.M.; Fireman, M.J.; Vandiver, R. Morning vs evening light treatment for winter depression. Evidence that the therapeutic effects of light are mediated by circadian phase shifts. Arch. Gen. Psychiatry, 1990, 47, 343-351
75. Checkley, S.A.; Murphy, D.G.; Abbas, M.; Marks, M.; Winton, F.; Palazidou, E.; Murphy, D.M.; Franey, C.; Arendt, J. Melatonin rhythms in seasonal affective disorder. Br. J. Psychiatry, 1993, 163, 332-337
76. Wirz-Justice, A.; Armstrong, S.M. Melatonin: nature's soporific? J. Sleep Res., 1996, 5, 137-141
77. Wehr, T.A.; Duncan, W.C., Jr.; Sher, L.; Aeschbach, D.; Schwartz, P.J.; Turner, E.H.; Postolache, T.T.; Rosenthal, N.E. A circadian signal of change of season in patients with seasonal affective disorder. Arch. Gen. Psychiatry, 2001, 58, 1108-1114
78. Lavoie, M.P.; Lam, R.W.; Bouchard, G.; Sasseville, A.; Charron, M.C.; Gagné, A.M.; Tremblay, P.; Filteau, M.J.; Hébert, M. Evidence of a biological effect of light therapy on the retina of patients with seasonal affective disorder. Biol. Psychiatry, 2009, 66, 253-258
79. Arendt, J.; Skene, D.J. Melatonin as a chronobiotic. Sleep Med. Rev., 2005, 9, 25-39
80. Cardinali, D.P.; Furio, A.M.; Reyes, M.P.; Brusco, L.I. The use of chronobiotics in the resynchronization of the sleep-wake cycle. Cancer Causes Control, 2006, 17, 601-609
81. Kayumov, L.; Brown, G.; Jindal, R.; Buttoo, K.; Shapiro, C.M. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom. Med., 2001, 63, 40-48
82. Dolder, C.R.; Nelson, M.; Snider, M. Agomelatine treatment of major depressive disorder. Ann. Pharmacother., 2008, 42, 1822-1831
83. Yous, S.; Andrieux, J.; Howell, H.E.; Morgan, P.J.; Renard, P.; Pfeiffer, B.; Lesieur, D.; Guardiola-Lemaitre, B. Novel naphthalenic ligands with high affinity for the melatonin receptor. J. Med. Chem., 1992, 35, 1484-1486
84. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.;, Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J.P.; Malpaux, B.; Guillaumet, G.; Lesieur, D.; Lefoulon, F.; Renard, P.; Delagrange, P.; Boutin, J.A. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 6, 553-561
85. Millan, M.J.; Gobert, A.; Lejeune, F.; Dekeyne, A.; Newman- Tancredi, A.; Pasteau, V.; Rivet, J.M.; Cussac, D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5- hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther., 2003, 306, 954-964
86. Duxon, M.S.; Flanigan, T.P.; Reavley, A.C.; Baxter, G.S.; Blackburn, T.P.; Fone, K.C. Evidence for expression of the 5- hydroxy-trypamine-2B receptor profile in the rat central nervous system. Neuroscience, 1997, 76, 323-329
87. Dubocovich, M.L. Drug evaluation: agomelatine targets a range of major depressive disorder symptoms. Curr. Opin. Investig. Drugs, 2006, 7, 670-680
88. Wu, L.; Qiu, Y.; Wang, B.; Yu, Y.; Zhu, Z. Asymmetric expression of melatonin receptor mRNA in bilateral paravertebral muscles in adolescent idiopathic scoliosis. Stud. Health Technol. Inform., 2006, 123, 129-134
89. Mason, R.; Brooks, A. The electrophysiological effects of melatonin and a putative melatonin antagonist (N-acetyltryptamine) on rat suprachiasmatic neurones in vitro. Neurosci. Lett., 1988, 95, 296-301
90. Claustrat, B.; Brun, J.; Chazot, G. The basic physiology and pathophysiology of melatonin. Sleep. Med. Rev., 2005, 9, 11-24
91. Moyer, R.W.; Kennaway, D.J. Immunohistochemical localization of serotonin receptors in the rat suprachiasmatic nucleus. Neurosci. Lett., 1999, 271, 147-150
92. Conway, S.; Canning, S.J.; Howell, H.E.; Mowat, E.S.; Barrett, P.; Drew, J.E.; Delagrange, P., Lesieur, D.; Morgan, P.J. Characterisation of human melatonin mt(1) and MT(2) receptors by CRE-luciferase reporter assay. Eur. J. Pharmacol., 2000, 390, 15-24
93. Papp, M.; Litwa, E.; Gruca, P.; Mocaer, E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol., 2006, 17, 9-18
94. Papp, M.; Gruca, P.; Boyer, P.A.; Mocaer, E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology, 2003, 28, 694-703
95. Millan, M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther., 2006, 110, 135-370
96. Zupancic, M.; Guilleminault, C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs, 2006, 20, 981-992
97. Hanoun, N.; Mocaer, E.; Boyer, P.A.; Hamon, M.; Lanfumey, L. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology, 2004, 47, 515-526
98. San, L.; Arranz, B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur. Psychiatry, 2008, 23, 396-402
99. Quera-Salva, M.A.; Vanier, B.; Chapotot, F. Effect of agomelatine on the sleep EEG in patients with major depressive disorders (MDD). Eur. Neuropsychopharmacol., 2005, 15(Suppl. 3), 435
100. Lopes, M.C.; Quera-Salva, M.A.; Guilleminault, C. Cycling alternating pattern, in the NREM sleep of patients within major depressive disorder: baseline results, and change overtime with a new antidepressant. Sleep Med., 2005, 6(Suppl 2), 87
101. Pandi-Perumal, S.R.; Moscovitch, A.; Srinivasan, V.; Spence, D.W.; Cardinali, D.P.; Brown, G.M. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine. Prog. Neurobiol., 2009, 88, 264-271
102. Guardiola-Lemaitre, B.; Lenegre, A.; Porsolt, R.D. Combined effects of diazepam and melatonin in two tests for anxiolytic activity in the mouse. Pharmacol. Biochem. Behav., 1992, 41, 405-408
103. Kopp, C.; Vogel, E.; Rettori, M. C.; Delagrange, P.; Misslin, R. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav. Pharmacol., 1999, 10, 73-83
104. Kopp, C.; Vogel, E.; Rettori, M.C.; Delagrange, P.; Misslin, R. Anxiolytic-like properties of melatonin receptor agonists in mice: involvement of MT1 and/or MT2 receptors in the regulation of emotional responsiveness. Neuropharmacology, 2000, 39, 1865-1871
105. Kennaway, D.J.; Moyer, R.W.; Voultsios, A.; Varcoe, T.J. Serotonin, excitatory amino acids and the photic control of melatonin rhythms and SCN c-FOS in the rat. Brain Res., 2001, 897, 36-43
106. Kennaway, D.J.; Moyer, R.W. Serotonin 5-HT2c agonists mimic the effect of light pulses on circadian rhythms. Brain Res., 1998, 806, 257-270
107. Riedel, W.J.; Klaassen, T.; Griez, E.; Honig, A.; Menheere, P.P.C.A.; Van Praag, H.M. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood. Neuropsychopharmacology, 2002, 26, 358-367
108. Imbesi, M.; Uz, T.; Yildiz, S.; Arslan, A.D.; Manev, H. Drug and region-specific effects of protracted antidepressant and cocaine treatment on the content of melatonin MT1 and MT2 receptor mRNA in the mouse brain. Int. J. Neuroprot. Neuroregener., 2006, 2, 185-189
109. European Medicines Agency. Evaluation of medicines for human use- CHMP Assessment Report For Valdoxan. http://www.emea.eu ropa.eu/humandocs/PDFs/EPAR/valdoxan/H-915-en6.pdf [Accessed December 26, 2009]
110. Loo, H.; Hale, A.; D'Haenen, H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol., 2002, 17, 239-247
111. Martinet, L.; Guardiola-Lemaitre, B.; Mocaer, E. Entrainment of circadian rhythms by S 20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol. Biochem. Behav., 1996, 54, 713-718
112. Fochtmann, L.G.; Gelenberg, A.J. In: Guideline Watch: Practice Guideline for the Treatment of Patients with Major Depressive Disorder; 2nd ed. American Psychiatric Association: Arlington, VA 2005, pp. 1-15
113. Rouillon, F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int. Clin. Psychopharmacol., 2006, 21(Suppl 1), 31-35
114. Montgomery, S.A. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur. Neuropsychopharmacol., 2006, 16, 633-638
115. Kennedy, S.H.; Emsley, R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol., 2006, 16, 93-100
116. Lemoine, P.; Guilleminault, C.; Alvarez, E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry, 2007, 68, 1723-1732
117. Kennedy, S.H.; Rizvi, S.; Fulton, K.; Rasmussen, J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J. Clin. Psychopharmacol., 2008, 28, 329-333
118. Montgomery, S.A.; Kennedy, S.H.; Burrows, G.D.; Lejoyeux, M.; Hindmarch, I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double- blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol., 2004, 19, 271-280
119. European Medicines Agency. Committee For Medicinal Products For Human Use summary Of Positive Opinion For Valdoxan. http://www.emea.europa.eu/pdfs/human/opinion/Valdoxan_57541108en.pdf [Accessed December 26, 2009]
120. Calabrese, J.R.; Guelfi, J.D.; Perdrizet-Chevallier, C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord., 2007, 9, 628-635
121. Howland, R.H. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr. Dis. Treat., 2009, 5, 563-576
122. Hamon, M.; Bourgoin, S. Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects? Eur. Neuropsychopharmacol., 2006, 16, 625-632
123. Wilson, S. Antidepressants and sleep. A qualitative review of the literature. Drugs, 2005, 65, 927-947
124. Grassi-Zucconi, G.; Semprevivo, M.; Carandente, F.; Mocaer, E.; Kristensson, K.; Bentivoglio, M. Melatonin and S-20098 improve sleep disorder and life expectancy in an animal model of sleeping sickness. In: Biological Clocks. Mechanisms and Applications; Touitou, Y., Ed.; Elsevier Science: Amsterdam, 1998, pp. 305-308
125. Lam, R.W. Sleep disturbances and depression: a challenge for antidepressants. Int. Clin. Psychopharmacol., 2006, 21, 25-29
126. Pjrek, E.; Winkler, D.; Konstantinidis, A.; Willeit, M.; Praschak- Rieder, N.; Kasper, S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology, 2007, 190, 575-579
127. Fuchsa, E.; Simon, M.; Schmelting, B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int. Clin. Psychopharmacol., 2006, 21, 17-20
128. Srinivasan, V.; Pandi-Perumal, S.R.; Trakht, I.; Spence, D.W; Hardeland, R.; Poeggeler, B.; Cardinali, D.P. Pathophysiology of depression: Role of sleep and the melatonergic system. Psychiatry Res., 2009, 165, 201-214
129. Montgomery, S.A.; Kasper, S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int. Clin. Psychopharmacol., 2007, 22, 283-291
130. Van Reeth, O.; Weibel, L.; Olivares, E.; Maccari, S.; Mocaer, E.; Turek, F.W. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 280, 1582-1591
131. Le Strat, Y.; Gorwood, P. Agomelatine, an innovative pharmacological response to unmet needs. J. Psychopharmacol., 2008, 22, 4-8
132. Millan, M.J.; Lejeune, F.; Gobert, A. Reciprocal autoreceptor and heteroreceptor control of serotonergic dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol., 2008, 14, 114-138
133. Bourin, M.; Prica, C. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. Curr. Pharm. Des., 2009, 15, 1675-1682
134. Bourin, M.; Mocaer, E.; Porsolt, R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: Involvement of melatonin and serotonin receptors. J. Psychiatry Neurosci., 2004, 29, 126-133
135. Gressens, P.; Schwendimann, L.; Husson, I.; Sarkozy, G.; Mocaer, E.; Vamecq, J.; Spedding, M. Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity. Eur. J. Pharmacol., 2008, 588, 58-63
136. Banasr, M.; Soumier, A.; Hery, M.; Mocaer, E.; Daszuta, A. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol. Psychiatry, 2006, 59, 1087-1096
137. Kodama, M.; Fujioka, T.; Duman, R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry, 2004, 56, 570-580
138. Molteni, R.; Calabrese, F.; Pisoni, S.; Gabriel, C.; Mocaer, E.; Racagni, G.; Riva, M.A. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J. Biol. Psychiatry, 2010, 11, 148-153
139. Olie, J.P.; Kasper, S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharmacol., 2007, 10, 661-673
140. Kasper, S.; Hajak, G.; Wulff, K.; Hoogendijk, W.J.; Montejo, A.L.; Smeraldi, E.; Rybakowski, J.K.; Quera-Salva, M.A.; Wirz-Justice, A.M.; Picarel-Blanchot, F.; Baylé, F.J. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J. Clin. Psychiatry, 2010, 71, 109-120
141. Hale, A.; Corral, R.; Mencacci, D.; Saiz Ruiz, J.; Gentil, V. Superior antidepressant efficacy of agomelatine vs fluoxetine in severe MDD patients: a randomised, double-blind study. Unpublished study, http://www.valdoxan.com/ [Accessed April 8, 2010]
142. Zajecka, J.; Schatzberg, A.; Stahl, S.M.; Shah, A.; Caputo, A.; Post, A. Efficacy and safety of agomelatine in the treatment of major depressive disorder. a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol., 2010, 30, 135-144
143. Stahl, S.M.; Fava, M.; Trivedi, M.H.; Caputo, A.; Shah, A.; Post, A. Agomelatine in the treatment of major depressive disorder: an 8- week, multicenter, randomized, placebo-controlled trial. J. Clin. Psychiatry, 2010, 71(5), 616-626
144. Goodwin, G.M.; Emsley, R.; Rembry, S.; Rouillon, F.; Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry, 2009, 70, 1128-1137
145. National Institutes of Health. ClinicalTrials.gov. Search for clinical trials. http://www.clinicaltrials.gov/ct2/results?term=agomelatine [Accessed April 8, 2010]
146. Quera Salva, M.A.; Vanier, B.; Laredo, J.; Hartley, S.; Chapotot, F.; Moulin, C.; Lofaso, F.; Guilleminault, C. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int. J. Neuropsychopharmacol., 2007, 10, 691-696
147. Lopes, M.C.; Quera-Salva, M.A.; Guilleminault, C. Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (agomelatine). Sleep Med., 2007, 9, 33-41
148. European Medicines Agency (2006). Evaluation of medicines for human use-refusal CHMP assessment and report for thymanax. http://www.emea.eu/humandocs/PDFs/EPAR/thymanax/H-657-RA R-en.pdf [Accessed April 8, 2010]
149. Stein, D.J.; Ahokas, A.A.; de Bodinat, C. Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol., 2008, 28, 561-566
150. Baldwin, D.S.; Lopes, A.T. Agomelatine in the treatment of mood and anxiety disorders. Br. J. Hosp. Med., 2010, 71, 153-156
151. McAllister-Williams, R.H.; Baldwin, D.S.; Haddad, P.M.; Bazire, S. The use of antidepressants in clinical practice: focus on agomelatine. Hum. Psychopharmacol., 2010, 25, 95-102
152. Popoli, M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs, 2009, 23(Suppl 2), 27-34
153. Kennedy, S.H. Agomelatine: efficacy at each phase of antidepressant treatment. CNS Drugs, 2009, 23(Suppl 2), 41-47.